Xenome Completes Financing to Advance Peptide-Based Pain Med

The current financing is intended to help with a Phase II placebo-controlled multicenter trial of Xen2174 in a post bunionectomy surgical patient population.

Australia-based biopharmaceutical company Xenome has completed a financing of A$8 million (roughly $6.22 million) to support the ongoing development of antipain medication Xen2174.

Xenome is developing Xen2174, a 13-amino acid synthetic peptide, for the management of moderate to severe pain. It has reportedly shown promise as a non-opiate pain therapeutic when administered intrathecally. The compound is a highly selective and non-competitive inhibitor of norepinephrine transporter (NET), a validated target for the management of pain.

The current financing is intended to help with a Phase II placebo-controlled multicenter trial of Xen2174 in a post bunionectomy surgical patient population.